Laura C. Coates
YOU?
Author Swipe
View article: Therapeutic Windows Across the Psoriatic Arthritis Spectrum
Therapeutic Windows Across the Psoriatic Arthritis Spectrum Open
PsA management is shifting from reactive to proactive care. Aligning clinical practice toward early detection of skin and joint disease, rapid access to appropriate biologics, and disciplined treat-to-target approaches offer the best prosp…
View article: Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials
Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials Open
ClinicalTrials.gov identifier NCT03162796, NCT03158285, NCT03796858.
View article: Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With Guselkumab
Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With Guselkumab Open
Objective To evaluate the validity of the 3-item Visual Analog Scale (3VAS) and 4VAS and determine the minimal clinically important difference (MCID) and minimal detectable change (MDC) for each measure using data from three phase 3 random…
View article: A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK
A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK Open
Objectives Evidence evaluating effectiveness of biologic and targeted synthetic DMARDs (b/tsDMARDs) in adults with PsA after exposure to three or more b/tsDMARDs is lacking. We aimed to evaluate response to sequential lines of b/tsDMARDs. …
View article: Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study Open
Guselkumab, a fully human monoclonal antibody able to bind CD64 and simultaneously inhibit the IL-23p19 subunit, provided significantly higher rates of clinical improvement and significant inhibition of structural damage progression versus…
View article: Effects of Acute Time-Restricted Eating on Inflammation in Individuals With Psoriasis: Protocol for a Case-Control, Prospective Study
Effects of Acute Time-Restricted Eating on Inflammation in Individuals With Psoriasis: Protocol for a Case-Control, Prospective Study Open
Background Psoriasis is a chronic inflammatory disease associated with multiple comorbidities, including metabolic syndrome and cardiovascular disease. Although specific dietary interventions, such as intermittent fasting and caloric restr…
View article: Interpretable Rheumatoid Arthritis Scoring via Anatomy-aware Multiple Instance Learning
Interpretable Rheumatoid Arthritis Scoring via Anatomy-aware Multiple Instance Learning Open
The Sharp/van der Heijde (SvdH) score has been widely used in clinical trials to quantify radiographic damage in Rheumatoid Arthritis (RA), but its complexity has limited its adoption in routine clinical practice. To address the inefficien…
View article: Ethnic disparities in COVID-19 mortality and cardiovascular disease in England and Wales between 2020-2022
Ethnic disparities in COVID-19 mortality and cardiovascular disease in England and Wales between 2020-2022 Open
An increased risk of COVID-19 mortality risk among certain ethnic groups is well-reported, however data on ethnic disparities in COVID-19-related cardiovascular disease (CVD) are lacking. We estimated age-standardised incidence rates and a…
View article: Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies Open
Objective To assess the efficacy of long-term treatment with risankizumab across the updated Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains and key related conditions of psoriatic arthritis (PsA). M…
View article: High prevalence of MASLD in psoriasis and psoriatic arthritis assessed with multiparametric magnetic resonance imaging
High prevalence of MASLD in psoriasis and psoriatic arthritis assessed with multiparametric magnetic resonance imaging Open
Objectives Psoriatic disease (PsD) is a chronic inflammatory condition associated with obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH). We aimed to determine the prevalence of MASLD/MASH…